肝素结合表皮生长因子在卵巢癌中的研究进展  

Progress in the Research of Heparin Binding-Epidermal Growth Factor in Ovarian Cancer

作　　者：汤小晗[1] 卢美松[1] 

机构地区：[1]哈尔滨医科大学附属第一医院妇产科,150001

出　　处：《国际妇产科学杂志》2012年第3期250-253,共4页Journal of International Obstetrics and Gynecology

基　　金：黑龙江省自然科学基金资助项目(ZD200906)

摘　　要：肝素结合表皮生长因子(HB-EGF)是表皮生长因子家族成员之一,可通过激活表皮生长因子受体发挥生物学效应。近来研究表明,HB-EGF在卵巢癌中高水平表达并在肿瘤的发生发展中起重要作用,因此成为极具潜力的卵巢癌治疗靶点。系统描述HB-EGF的特性及其特异性抑制剂白喉毒素突变体(CRM197)的研究现状,并讨论CRM197分别和膜型基质金属蛋白酶(MTl-MMP)抑制剂、去整合素-金属蛋白酶(ADAM)抑制剂及紫杉醇联合治疗卵巢癌的发展潜力。Heparin binding-epidermal growth factor-like growth factor（HB-EGF）,a member of the EGF family of growth factors,exerts its diverse biological activities through activation of the EGFR.Recently studies revealed HB-EGF expression was significantly elevated in ovarian cancer and it played a key role in the development of tumor,so HB-EGF was considered as a potential target for ovarian cancer therapy.The features of HB-EGF and the research progress of HB-EGF specific inhibitor CRM197 in therapy of ovarian cancer will be reviewed.We will also discuss the future direction for the development of therapeutic strategies targeting CRM197 and MTI-MMP inhibitor,ADAMs inhibitor,paclitaxel respectively.

关 键 词：卵巢肿瘤 表皮生长因子 受体 表皮生长因子 肿瘤治疗方案 肝素结合表皮生长因子 

分 类 号：R737.31[医药卫生—肿瘤]